Stocks and Investing
Stocks and Investing
Mon, May 1, 2023
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
[ Mon, May 01st 2023
] - WOPRAI
Andrew Fein Reiterated (TARA) at Strong Buy and Held Target at $23 on, May 1st, 2023
Andrew Fein of HC Wainwright & Co., Reiterated "Protara Therapeutics, Inc." (TARA) at Strong Buy and Held Target at $23 on, May 1st, 2023.
Andrew, nor any peers, have made any analyst calls on TARA in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources